Paul Moseley Selected Research

Therapeutics

1/2020	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
1/2019	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
12/2017	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.
1/2015	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
12/2014	ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
5/2014	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
12/2013	Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Moseley Research Topics

Disease

10	Breast Neoplasms (Breast Cancer) 06/2018 - 12/2013
9	Neoplasms (Cancer) 01/2019 - 01/2013
6	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2013
5	Ovarian Epithelial Carcinoma 01/2021 - 10/2014
2	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2014 - 01/2013
1	Disease Progression 06/2018
1	Serous Cystadenocarcinoma 12/2014

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2015 - 02/2014
5	Messenger RNA (mRNA)IBA 01/2015 - 12/2013
4	PlatinumIBA 01/2021 - 12/2014
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 10/2014
3	Trastuzumab (Herceptin)FDA Link 12/2017 - 04/2014
3	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 01/2015 - 07/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 07/2014
2	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2021 - 05/2014
2	Poly (ADP-Ribose) Polymerase-1IBA 01/2020 - 01/2019
2	olaparibIBA 01/2020 - 01/2019
2	Cisplatin (Platino)FDA LinkGeneric 01/2015 - 01/2013
2	DNA-Activated Protein KinaseIBA 12/2014 - 07/2014
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021
1	rucaparibIBA 01/2020
1	talazoparibIBA 01/2020
1	niraparibIBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2018
1	PCTAIRE-3 protein kinaseIBA 06/2018
1	Tumor Biomarkers (Tumor Markers)IBA 12/2017
1	RNA Precursors (Precursor, mRNA)IBA 12/2017
1	Indicators and Reagents (Reagents)IBA 12/2017
1	RNA Splicing FactorsIBA 12/2017
1	RecQ HelicasesIBA 03/2016
1	Ataxia Telangiectasia Mutated ProteinsIBA 12/2014
1	X-ray Repair Cross Complementing Protein 1IBA 12/2014
1	CDC2 Protein Kinase (Protein p34cdc2)IBA 12/2014
1	Flap EndonucleasesIBA 10/2014
1	human ERBB2 proteinIBA 05/2014
1	EndonucleasesIBA 02/2014
1	Uracil-DNA GlycosidaseIBA 12/2013
1	Protein Kinases (Protein Kinase)IBA 01/2013
1	4- cyclohexylmethoxy- 5- nitrosopyrimidine- 2,6- diamineIBA 01/2013
1	Single-Stranded DNA (DNA, Single Stranded)IBA 01/2013

Therapy/Procedure

7	Therapeutics 01/2020 - 12/2013
2	Ligation 05/2014 - 04/2014
1	Drug Therapy (Chemotherapy) 06/2018